Portal de Periódicos da CAPES

Glycemic control and maternal and fetal outcomes in pregnant women with type 1 diabetes according to the type of basal insulin

2016; Elsevier BV; Volume: 206; Linguagem: Inglês

10.1016/j.ejogrb.2016.07.490

1872-7654

Ana Chico, Lucrecia Herranz, Rosa Corcoy, O. Ramírez, María Goya, Jordi Bellart, Stella González‐Romero, Mercè Codina, P. Sánchez SÁNchez, Alicia Cortázar, Domingo Acosta, María José Picón César, José Antonio Rubio, Ana Megía, M.A. Sancho, Mercè Fernández-Balsells, Eva Solá, Nieves Luisa González González, J. López-López,

Birth, Development, and Health

Abstract Objective To examine the potential role of the type of basal insulin on glycemic control and maternal and foetal outcomes in pregnant women with type 1 diabetes (T1DM). Study design Retrospective cohort study of pregnancies attended at 18 Spanish tertiary hospitals. Inclusion criteria T1DM, singleton pregnancies, delivery between 2002–2010, and use of the same basal and prandial insulin from before pregnancy until delivery. Results A total of 1534 pregnancies were included. The basal insulin most commonly used was Neutral Protamine Hagedorn (NPH) (51.7%), followed by glargine (23.2%) and continuous subcutaneous insulin infusion (CSII) (21.1%). CSII users had longer diabetes duration. Multiple logistic regression analysis showed that CSII was independently associated with lower doses of insulin, higher glycated haemoglobin (HbA 1c ) in all trimesters, and higher rates of miscarriage, preterm birth and neonatal hypoglycemia. Glargine was related to a higher risk of preterm birth and a small-for-gestational age infant (SGA). The odds ratios (OR) of the associations between insulin type and clinical outcomes (from 0.642 to 4.894) have a relevant magnitude. Conclusions In this observational study of pregnant women with T1DM, the type of basal insulin was independently associated with metabolic variables and foetal outcomes.